Abstract: Compositions may be used in treating or preventing a virus infection in a subject, wherein the virus is from the Coronaviridae family and wherein the composition includes an extract of black currants and/or bilberries. The black currants may be the fruit of Ribes nigrum, and/or the bilberries may be the fruit of Vaccinium myrtillus. The extract may be of the pomaces of the black currants and/or the bilberries.

Abstract: A process for generating thermal energy and basic chemicals having the following steps: a) producing aluminum metal by fused-salt electrolysis in a fused-salt electrolysis plant, b) using aluminum metal for the generation of thermal energy and of chemical basic materials selected from the group carbon monoxide or hydrogen, by bringing carbon dioxide and/or water or a mixture containing a compound containing nitrogen and hydrogen and carbon dioxide and/or water into contact with the aluminum metal and converting it in an aluminothermic reaction to aluminum oxide and carbon monoxide and/or hydrogen, c) storage or chemical conversion of the carbon monoxide and/or hydrogen produced thereby, d) storage of the thermal energy generated in the process or conversion into other forms of energy, and e) recycling the aluminum oxide obtained in the process to the fused-salt electrolysis.

Abstract: A body has multiple phases, which have different electron spin resonance spectra that do not result from the simple combination of the ESR spectra of each individual phase.

Abstract: A method of unambiguous identification and authentication of products for the purpose of better recognition of product forgeries and controlling product piracy, including applying to/into the product an identification substance admixture which contains paramagnetic phases or identifying a product which contains an identification substance admixture containing paramagnetic phases and has an ESR fingerprint spectrum that permits unambiguous identification of the product. Such an ESR fingerprint spectrum is easily measurable, but can be copied or forged only with difficulty. The method relates to an individualizable “femto tag” for femto ledgers and forms an important interface for what are known as “Internet of Things” (IOT).

Abstract: A composition may be used in treating or preventing a virus infection in a subject, wherein the virus is from the Herpesviridae family and wherein the composition includes an extract of black currants and bilberries. The composition may contain an extract from black currants and bilberries in a weight ratio of 0.5:1 to 1:0.

Abstract: A composition may be used in treating or preventing a virus infection in a subject, wherein the virus is from the Paramyxoviridae family and wherein the composition includes an extract of black currants and bilberries. The composition may contain an extract from black currants and bilberries in a weight ratio in a range of from 0.5:1 to 1:0.5. The extract may be an alcoholic extract, such as a methanol extract. The composition may be administered to the subject 1 to 10 oral dosages of at least 80 mg anthocyanins each per day, preferably 3 to 6 oral dosages of at least 80 mg anthocyanins each per day. The subject may not have received a measles vaccination or have previously been exposed to the measles virus.

Abstract: The present invention is related to composition for use in treating or preventing a cancer in a subject, wherein the cancer comprises cancer cells that are CD4+, and wherein the composition comprises one or more of an extract of black currants, an extract of bilberries, and an anthocyanin.

Abstract: Combined preparations including an anthocyanin composition and an antiviral agent for use in treating or preventing a virus infection in a subject, wherein the anthocyanin composition includes an extract of black currants, an extract of bilberries, an extract of red grapes, and/or delphinidin 3 glucoside, wherein the virus is from the Herpesviridae family and the antiviral agent is a Herpesviridae antiviral agent, and wherein the anthocyanin composition and the antiviral agent are for simultaneous, separate or sequential use.

Abstract: The present invention is related to Delphinidin-3-glucoside (D3G) for use in treating or preventing a vims infection in a subject, wherein the virus is from the Herpesviridae family.

Abstract: A preparation containing a mixture of at least one phospholipid, and at least one fatty acid salt of a cation with an anion derived from a fatty acid. A method for preparing such preparation and the use of such preparation to provide polyunsaturated fatty acids to cells, tissues, organs or organisms, for example in the field of cell and tissue culture, organ preservation, human or animal nutrition, or cosmetics.

Abstract: A body has multiple phases, which have different electron spin resonance spectra that do not result from the simple combination of the ESR spectra of each individual phase.

Abstract: An injection solution contains an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent and a pharmaceutical active ingredient which is non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups. The content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.

Abstract: An injection solution can be used in a pharmaceutical dosage formulation. The injection solution includes an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent, and a pharmaceutical active ingredient, which is a non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, and which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups, where a content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.

Abstract: A process for preparing a powder, which includes one or more human coagulation factor proteins and a lactic acid polymer, involves mixing and dispersing a lactic acid polymer with a particle size d50 in the range 0.1-2 ?m and the one or more human coagulation factor proteins in water. The dispersion is dried, and the resulting dried mass is compressed. The resulting compressed dried mass is comminuted to a powder with a particle size d50 in the range of more than 0.5 and up to 5 ?m.

Abstract: An injection solution can be used in a pharmaceutical dosage formulation. The injection solution includes an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent, and a pharmaceutical active ingredient, which is a non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, and which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups, where a content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.

Abstract: A process for preparing a powder, which includes one or more human coagulation factor proteins and a lactic acid polymer, involves mixing and dispersing a lactic acid polymer with a particle size d50 in the range 0.1-2 ?m and the one or more human coagulation factor proteins in water. The dispersion is dried, and the resulting dried mass is compressed. The resulting compressed dried mass is comminuted to a powder with a particle size d50 in the range of more than 0.5 and up to 5 ?m.

Abstract: The invention refers to a human lactoferrin derived peptide for use as an antigen masking agent in the production of a pharmaceutical composition for delivery of a biological active substance in a mammalian organism, where the biological active substance is able to induce an undesired immune response by the mammalian organism, where the pharmaceutical composition comprises a supramolecular aggregate of the biological active substance and the human lactoferrin derived peptide, with the effect that after delivery of pharmaceutical composition to the mammalian organism, there is no or only a diminished induction of the undesired immune response against the biological active substance.

Abstract: The subject matter of the invention is a detector system for detecting magnetic bodies in the human organism, which comprises at least two sensor assemblies, wherein each sensor assembly has one, two or three anisotropic magnetic resistance sensors, of which the axes of weak magnetization point in different directions in pairs, and each sensor assembly has a spacing of 0.5 to 50 cm from the sensor assembly or the other sensor assemblies, and at least two sensor assemblies are tilted at an angle of 0 to 45° with respect to one another, and in addition a method for detecting the magnetic flux produced by a magnetic body in the human organism, and the use of the detector system according to the invention for detecting swallowed magnetic bodies and the disintegration of the same in the digestive system.

Abstract: The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterized in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another.

Abstract: A peptide having an amino acid sequence containing at least eight consecutive amino acids of the human lactoferrin protein or of the bovine lactoferrin protein. The peptide is suitable as a cell-penetrating peptide. A complex of the peptide and a cargo molecule non-covalently bound to the peptide. The cargo molecule may be a nucleic acid, an amino acid, a peptide, a protein, a carbohydrate, a lipid, or a small molecule. A method of penetrating or transfecting a cell using the complex.